LEXINGTON, Mass., Sept. 27, 2017 /PRNewswire/ -- Aldeyra
Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn
errors of metabolism, and other diseases related to endogenous aldehyde toxicity today announced that it will host a Research and
Development Day to discuss new clinical results from the Company's Phase 2 clinical trials in allergic conjunctivitis and dry eye
disease, as well as market opportunities in ocular inflammation. The agenda will include key opinion leaders
John Sheppard, M.D., Professor of Ophthalmology at Eastern Virginia Medical
School and President, Virginia Eye Consultants; Gary Novack, PhD, President, PharmaLogic
Development, Inc. and Visiting Professor of Pharmacology and Ophthalmology, University of California,
Davis, School of Medicine; and Tim Surgenor, Partner at Red Sky Partners, LLC.
Management and speaker presentations will begin at 9:00 a.m. Eastern Time on Monday, October 10, 2017 at the offices of Dechert, LLP in New York City.
A live webcast of the presentation and slide deck will be available via the Company's Investor Relations website at http://ir.aldeyra.com. Following the live webcast, an archived
version will be available on the website until October 10, 2018.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and
commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of
pro-inflammatory and toxic molecules. Aldeyra's lead product candidate, ADX-102, is an aldehyde trap in development as
topical eye drops for the treatment of ocular inflammation. ADX-102 has now been tested in over 250 patients in Phase 2 clinical
trials in dry eye disease, allergic conjunctivitis, and noninfectious anterior uveitis. A dermatologic form of ADX-102 is in
late-stage clinical development for the treatment of ichthyosis due to Sjögren-Larsson Syndrome, an inborn error of aldehyde
metabolism. ADX-102 has not been approved for sale in the U.S. or elsewhere.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including statements regarding Aldeyra's plans and expectations for the
development of ADX-102 and the timing thereof; the potential of ADX-102 as an agent for the treatment of dry eye disease; the
ability of ADX-102 to provide important patient benefits and a differentiated mechanism of action relative to existing therapies;
and estimates of the market size for Dry Eye Disease. Aldeyra intends such forward-looking statements to be covered by the safe
harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as "may,"
"might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "anticipate," "project,"
"target," "design," "estimate," "predict," "potential," "aim," "plan" or the negative of these terms, and similar expressions
intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve
risks, changes in circumstances, assumptions and uncertainties. Aldeyra is at an early stage of development and may not ever have
any products that generate significant revenue. Important factors that could cause actual results to differ materially from those
reflected in Aldeyra's forward-looking statements include, among others, the timing of enrollment, commencement and completion of
Aldeyra's clinical trials, the timing and success of preclinical studies and clinical trials conducted by Aldeyra and its
development partners; updated or refined data based on Aldeyra's continuing review and quality control analysis of clinical data,
Aldeyra's ability to design clinical trials with protocols and endpoints acceptable to applicable regulatory authorities, the
ability to obtain and maintain regulatory approval to conduct clinical trials and to commercialize Aldeyra's product candidates,
and the labeling for any approved products; the scope, progress, expansion, and costs of developing and commercializing Aldeyra's
product candidates; the size and growth of the potential markets for Aldeyra's product candidates and the ability to serve those
markets; Aldeyra's expectations regarding Aldeyra's expenses and revenue, the sufficiency of Aldeyra's cash resources and needs
for additional financing; the rate and degree of market acceptance of any of Aldeyra's product candidates; Aldeyra's expectations
regarding competition; Aldeyra's anticipated growth strategies; Aldeyra's ability to attract or retain key personnel; Aldeyra's
ability to establish and maintain development partnerships; Aldeyra's expectations regarding federal, state and foreign
regulatory requirements; regulatory developments in the United States and foreign countries; Aldeyra's ability to
obtain and maintain intellectual property protection for its product candidates; the anticipated trends and challenges in
Aldeyra's business and the market in which it operates; and other factors that are described in the "Risk Factors " and
"Management's Discussion and Analysis of Financial Condition and Results of Operations " sections of Aldeyra's Annual Report on
Form 10-K for the year ended December 31, 2016 and Quarterly Report on Form 10-Q for the quarter ended June 30,
2017, which are on file with the Securities and Exchange Commission(SEC) and available on the SEC's website
at www.sec.gov. All of Aldeyra's development timelines may
be subject to adjustment depending on recruitment rate, regulatory review, preclinical and clinical results, and other factors
that could delay the initiation or completion of clinical trials.
In addition to the risks described above and in Aldeyra's other filings with the SEC, other unknown or unpredictable
factors also could affect Aldeyra's results. No forward-looking statements can be guaranteed and actual results may differ
materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra
undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future
events, or otherwise, except as required by law.
Corporate Contact:
Stephen Tulipano
Aldeyra Therapeutics, Inc.
Tel: +1 781-761-4904 ext. 205
stulipano@aldeyra.com
Investor Contact:
Chris Brinzey
Westwicke Partners
Tel: 339-970-2843
Chris.brinzey@westwicke.com
Media Contact:
Cammy Duong
MacDougall Biomedical Communications
781-591-3443
cduong@macbiocom.com
View original content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-announces-2017-research-and-development-day-300526232.html
SOURCE Aldeyra Therapeutics, Inc.